Who Buys Amphotericin from India — 390 Importers Behind a $88.0M Market

The 390 buyers of Amphotericin from India can be categorized into several segments:

1. Pharmaceutical Companies: Entities like SUN PHARMACEUTICAL INDUSTRIES, INC. (United States) and SUN PHARMA ANZ PTY LIMITED (Australia) are pharmaceutical manufacturers that procure Amphotericin for inclusion in their product portfolios. Their purchasing patterns are characterized by large, consistent orders to meet production demands.

2. Distributors: Companies such as TILLOMED LABORATORIES LTD (United Kingdom) and MAXXCARE COMPANY LIMITED (Vietnam) function as intermediaries, supplying Amphotericin to healthcare providers and pharmacies. They typically place regular orders, adjusting volumes based on market demand and inventory levels.

3. Government Procurement Agencies: Organizations like the MINISTERIO DA SAUDE/DEPARTAMENTO DE (Brazil) are responsible for national healthcare procurement. Their purchasing behavior involves large-volume orders, often through tender processes, to ensure adequate public health supply.

4. Hospital Groups and Healthcare Providers: While not explicitly listed among the top buyers, some hospital groups may directly import Amphotericin to meet specific patient needs, especially in regions with high incidences of fungal infections. Their orders are typically smaller and more sporadic, aligned with immediate clinical requirements.

5. Re-exporters: Certain buyers may import Amphotericin with the intent to re-export to neighboring countries, leveraging regional trade agreements. Their purchasing patterns are influenced by both domestic and regional market demands.

6. Contract Manufacturers: Some entities procure Amphotericin to manufacture finished pharmaceutical products on behalf of other companies. Their orders are project-based, varying with contractual obligations.

The repeat buyer rate of 51.5% indicates a stable demand, with over half of the buyers returning for subsequent purchases, reflecting the essential nature of Amphotericin in treating severe fungal infections.

For the top five importing countries, the import regulations for Amphotericin are as follows:

The demand for Amphotericin in importing countries is driven by several factors:

1. Disease Prevalence: Amphotericin is a critical antifungal used to treat severe fungal infections such as cryptococcal meningitis and systemic candidiasis. Regions with high incidences of these infections, often due to HIV/AIDS prevalence, have increased demand for Amphotericin.

2. Government Healthcare Programs: Many countries have national health programs that prioritize the treatment of life-threatening infections. For instance, the Global Fund to Fight AIDS, Tuberculosis and Malaria includes Amphotericin in its procurement list to combat opportunistic infections in HIV patients.

3. Universal Health Coverage Expansion: As countries expand their healthcare coverage, access to essential medicines like Amphotericin becomes a priority, leading to increased procurement to meet the needs of the population.

4. WHO Essential Medicines List Procurement: Amphotericin is listed on the WHO Model List of Essential Medicines, guiding countries in their procurement decisions to ensure availability of vital treatments.

5. Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender processes to ensure cost-effectiveness and supply security. This method is commonly used for essential medicines, including Amphotericin, to manage public health needs efficiently.

The presence of 390 buyers across 116 countries underscores the global reliance on Amphotericin to address critical healthcare challenges, presenting ongoing market opportunities for suppliers.

The 390 buyers of Amphotericin from India can be categorized into several segments:

1. Pharmaceutical Companies: Entities like SUN PHARMACEUTICAL INDUSTRIES, INC. (United States) and SUN PHARMA ANZ PTY LIMITED (Australia) are pharmaceutical manufacturers that procure Amphotericin for inclusion in their product portfolios. Their purchasing patterns are characterized by large, consistent orders to meet production demands.

2. Distributors: Companies such as TILLOMED LABORATORIES LTD (United Kingdom) and MAXXCARE COMPANY LIMITED (Vietnam) function as intermediaries, supplying Amphotericin to healthcare providers and pharmacies. They typically place regular orders, adjusting volumes based on market demand and inventory levels.

3. Government Procurement Agencies: Organizations like the MINISTERIO DA SAUDE/DEPARTAMENTO DE (Brazil) are responsible for national healthcare procurement. Their purchasing behavior involves large-volume orders, often through tender processes, to ensure adequate public health supply.

4. Hospital Groups and Healthcare Providers: While not explicitly listed among the top buyers, some hospital groups may directly import Amphotericin to meet specific patient needs, especially in regions with high incidences of fungal infections. Their orders are typically smaller and more sporadic, aligned with immediate clinical requirements.

5. Re-exporters: Certain buyers may import Amphotericin with the intent to re-export to neighboring countries, leveraging regional trade agreements. Their purchasing patterns are influenced by both domestic and regional market demands.

6. Contract Manufacturers: Some entities procure Amphotericin to manufacture finished pharmaceutical products on behalf of other companies. Their orders are project-based, varying with contractual obligations.

The repeat buyer rate of 51.5% indicates a stable demand, with over half of the buyers returning for subsequent purchases, reflecting the essential nature of Amphotericin in treating severe fungal infections.

For the top five importing countries, the import regulations for Amphotericin are as follows:

The demand for Amphotericin in importing countries is driven by several factors:

1. Disease Prevalence: Amphotericin is a critical antifungal used to treat severe fungal infections such as cryptococcal meningitis and systemic candidiasis. Regions with high incidences of these infections, often due to HIV/AIDS prevalence, have increased demand for Amphotericin.

2. Government Healthcare Programs: Many countries have national health programs that prioritize the treatment of life-threatening infections. For instance, the Global Fund to Fight AIDS, Tuberculosis and Malaria includes Amphotericin in its procurement list to combat opportunistic infections in HIV patients.

3. Universal Health Coverage Expansion: As countries expand their healthcare coverage, access to essential medicines like Amphotericin becomes a priority, leading to increased procurement to meet the needs of the population.

4. WHO Essential Medicines List Procurement: Amphotericin is listed on the WHO Model List of Essential Medicines, guiding countries in their procurement decisions to ensure availability of vital treatments.

5. Tender-Based Purchasing: Many governments and large healthcare organizations procure medicines through tender processes to ensure cost-effectiveness and supply security. This method is commonly used for essential medicines, including Amphotericin, to manage public health needs efficiently.

The presence of 390 buyers across 116 countries underscores the global reliance on Amphotericin to address critical healthcare challenges, presenting ongoing market opportunities for suppliers.